Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG.

Slides:

Advertisements

Similar presentations

CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia by Peter Rhein, Rita Mitlohner,

Advertisements

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.

Allogeneic stem cell transplantation for adult Philadelphia chromosome–negative acute lymphocytic leukemia: comparable survival rates but different risk.

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.

Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.

Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? by Ching-Hon Pui, Charles G. Mullighan, William E. Evans, and Mary.

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Maury S et al. Proc ASH 2015;Abstract 1.

Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate-

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of.

A Prospective Randomized Trial of Buffy Coat Versus CD34-Selected Autologous Bone Marrow Support in High-Risk Breast Cancer Patients Receiving High-Dose.

Megan Othus, Frederick R. Appelbaum, Stephen H. Petersdorf, Kenneth J

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic.

Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21)‏ by Anthony V. Moorman, Susan.

Gupta V, Tallman MS, Weisdorf DJ

Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and.

Hypodiploidy With Less Than 45 Chromosomes Confers Adverse Risk in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Cancer Group by.

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants by.

Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993.

How I treat elderly patients with myeloma

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

A Phase 2 Study of Bortezomib Combined with Reinduction Chemotherapy in Children and Young Adults with Recurrent, Refractory or Secondary Acute Myeloid.

Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.

The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.

In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first.

Molecular Classifiers for Prediction of Minimal Residual Disease (MRD) and Event Free Survival (EFS) Improve Risk Assignment at Diagnosis in Pediatric.

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic.

Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is.

Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies by Sabine Kayser, Manuela Zucknick,

Final Report Of Single-Center Study Of Chemotherapy Plus Dasatinib For The Initial Treatment Of Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic.

Patient-Reported Outcomes from a Global Phase 3 Randomized Controlled Trial of Inotuzumab Ozogamicin Versus Standard of Care Chemotherapy for Relapsed/Refractory.

Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Age Years with Acute Myelogenous Leukemia in First.

Low Dose Thymoglobulin Results In Improved Outcomes After Allogeneic Unrelated Hematopoietic Stem Cell Transplantation (HCT) For Patients With Acute Myeloid.

by Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J

First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation

Jacob M. Rowe Biology of Blood and Marrow Transplantation

The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell.

Pretransplantation Consolidation Chemotherapy Decreases Leukemia Relapse after Autologous Blood and Bone Marrow Transplants for Acute Myelogenous Leukemia.

Autologous Is Superior to Allogeneic Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia in Second Complete Remission Jennifer L. Holter.

A Comparison of Cyclophosphamide and Total Body Irradiation with Etoposide and Total Body Irradiation as Conditioning Regimens for Patients Undergoing.

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia.

Overall survival by SCT versus observation in first complete remission

Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center for International.

Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic.

The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Myelogenous Leukemia in Adults: An Evidence-Based Review

Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity by Mary Eapen, Ruta Brazauskas, Michael.

Unrelated Donor Allogeneic Transplantation after Failure of Autologous Transplantation for Acute Myelogenous Leukemia: A Study from the Center for International.

US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL by Farhad Ravandi, Megan.

A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients by Alan K. Burnett,

Equivalent Survival for Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia John Moore, Ian Nivison-Smith,

Twenty-Year Follow-Up of a Controlled Trial Comparing a Combination of Methotrexate Plus Cyclosporine with Cyclosporine Alone for Prophylaxis of Graft-versus-Host.

Eliane Gluckman Experimental Hematology

Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia by Rosemary E. Gale,

Outcomes of Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adults Compared with Children and Older Adults with Acute Myeloid Leukemia

The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Lymphoblastic Leukemia in Adults: An Evidence-based.

Timing for HCT Consultation

TP53 Mutations in AML Predict Adverse Outcome in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant by Bartlomiej M Getta, Arnab Ghosh,

by Jan J. Cornelissen, and Didier Blaise

Health-Related Quality of Life (HRQoL) of Blinatumomab Versus Standard of Care (SOC) Chemotherapy in Patients with Relaspsed or Refractory Philadelphia.

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and.

How I treat T-cell acute lymphoblastic leukemia in adults

Cold agglutinin disease

Presentation transcript:

Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993 by Jacob M. Rowe, Georgina Buck, Alan K. Burnett, Raj Chopra, Peter H. Wiernik, Susan M. Richards, Hillard M. Lazarus, Ian M. Franklin, Mark R. Litzow, Niculae Ciobanu, H. Grant Prentice, Jill Durrant, Martin S. Tallman, and Anthony H. Goldstone Blood Volume 106(12):3760-3767 December 1, 2005 ©2005 by American Society of Hematology

A simplified overall schema of the study. A simplified overall schema of the study. MUD indicates matched unrelated donor transplantation; HD MTX, high-dose methotrexate. Jacob M. Rowe et al. Blood 2005;106:3760-3767 ©2005 by American Society of Hematology

Overall survival for all patients. Overall survival for all patients. (A) This study. (B) Ph status. Jacob M. Rowe et al. Blood 2005;106:3760-3767 ©2005 by American Society of Hematology

Overall survival for all patients in CR and for the 22 patients who did not achieve CR at the end of induction therapy. . Overall survival for all patients in CR and for the 22 patients who did not achieve CR at the end of induction therapy. Jacob M. Rowe et al. Blood 2005;106:3760-3767 ©2005 by American Society of Hematology

Patients at standard risk had better overall survival rates from the time of diagnosis. Patients at standard risk had better overall survival rates from the time of diagnosis. This included (A) all patients and (B) patients who achieved CR. Jacob M. Rowe et al. Blood 2005;106:3760-3767 ©2005 by American Society of Hematology

Overall survival by time to achieve CR. . Jacob M. Rowe et al. Blood 2005;106:3760-3767 ©2005 by American Society of Hematology

Overall survival by age. . Jacob M. Rowe et al. Blood 2005;106:3760-3767 ©2005 by American Society of Hematology

Overall survival by immunophenotype. . Jacob M. Rowe et al. Blood 2005;106:3760-3767 ©2005 by American Society of Hematology